Key Takeaways
- Record H1, margin leap: Standalone revenue up 32% YoY, PAT up 36% YoY, with EBITDA margin expanding 100 bps to 27.8% on operating leverage; consolidated H1 PAT of ₹144 crores nearly matched all of FY24.
- Subsidiaries turning the corner: IMPCO grew 14% on a high base, GSK China is improving and repaying debt, while Australia is believed to have bottomed and is pivoting to B2C products for a hockey-stick recovery.
- A large receivable has soured: A ₹44 crore overdue from a long-standing, large modern-trade distributor has forced legal action, a surprise default that management is pursuing aggressively with an uncertain recovery timeline.
- Capital efficiency remains extreme: Standalone trailing 12-month PBIT of ₹252 crores sits on negative capital employed of ₹171 crores, a figure that would be even stronger without the delayed domestic receivable.
- What to watch next quarter: Billing of 17 new air cooler models starting December, early traction in the water heater foray, and any progress on recovery from the defaulting distributor or monetization of reclassified real estate.
Performance & Profitability
- Standalone engine: Revenue grew 32% YoY, driven by good off-take during the off-season after a robust summer that left trade inventory below normal, which helped Q2 performance.
- Margin walk: EBITDA margin improved from 26.8% to 27.8% mainly on operating leverage; other expenses rose in line with turnover, including warranty, freight and warehousing costs.
- Consolidated lift: Consolidated EBITDA margin jumped ~500 bps and PAT margin rose 500 bps to 17.7%, outperforming standalone on better subsidiary-level realizations even though subsidiary profitability remains sub-par; GP margins improved 3.30 percentage points.
- H1 milestone: Highest ever September-quarter revenue and EBITDA on both standalone and consolidated bases; six-month consolidated PAT of ₹144 crores almost equals the entire FY 23-24 consolidated PAT of ₹148 crores.
- Capital philosophy: Standalone negative capital employed of ₹171 crores supports a trailing 12-month PBIT of ₹252 crores; consolidated capital employed in the core business is ~₹300 crores despite major growth.
Nrupesh Shah: "Symphony clearly believes that top line is vanity, profit is sanity, but cash flow and cash profit is really a purity and reality."
Subsidiary Health & Turnaround
- IMPCO leads: The Mexico subsidiary delivered 14% growth on a high base, continuing strong momentum.
- GSK China improving: Performance is continuously improving, driven by a combination of outsourcing from China to other markets and domestic business; the subsidiary has started repaying its loan, with ₹11 crores repaid in H1 out of ₹63 crores, leaving a balance of ~₹52 crores with clear visibility of additional repayment.
- Climate Technologies headwinds: Demand headwinds persist, but the business transformation is progressing as planned and EBITDA is contained despite lower revenue due to a reduced cost of doing business.
- Australia bottoming out: Revenue was knocked by external factors as the Australian economy was severely affected post-COVID and many builders, key customers for air cooling and central heating products, went bust; management believes the bottom has been reached and the subsidiary is pivoting to B2C products like air conditioners, portable air conditioners, electric heaters, panel heaters, gas heaters and fireplaces that do not depend on the builder segment.
Achal Bakeri: "It has taken longer than we had anticipated for a variety of reasons. But we believe that there too, it is like a hockey stick curve. And once we sort of touch the bottom, which we believe we have. Going forward, it will only -- the performance will only be significantly better."
The Defaulting Distributor
- The receivable: A major overdue from a large distributor of modern trade, a relationship held since 2013 with an impeccable track record until summer 2023, has not honoured its July-September payment schedule; legal action under Section 138 proceedings has been initiated with further legal steps planned.
- Scale of the counterparty: The party had group-level turnover in excess of ₹2,000 crores and had been a distributor for more than 12 years, making the default a major surprise to management.
- Recovery uncertain: Management declined to name the distributor, disclose any security deposit or collateral held, or confirm whether the distributor is regional or pan-India, citing legal sensitivity; on recovery prospects, the stance is "our guess is as good as yours" and the matter is partly sub-judice.
- Capital impact: The delayed domestic receivable has worsened what would otherwise have been an even stronger negative capital employed position on the standalone balance sheet.
Nrupesh Shah: "this was the party having a turnover in excess of ₹2,000 crores at a group level -- they were our distributor for more than 12 years. And until last summer, they were having impeccable track record in terms of the repayment. So, this has come as a major surprise to us also."
Product & Category Expansion
- New cooler models: 17 new models of air coolers launched and well received, with billing and delivery starting from the December quarter; introductions include "Silenzo," claimed to be the most silent air cooler available, and a range of commercial coolers aimed at the unorganized sector.
- Water heater foray: The company has entered the water heaters category in selected geographies with a very promising response from trade partners; management expects very positive performance down the line.
- De-risking the summer dependency: The air cooler category is an impulse buy sold primarily when temperatures hit 42-44°C, making it heavily seasonal; Symphony is de-risking through tabletop models that sell year-round, distribution channel diversification, large-space ventilated and centralized ducted air-cooling, and geographical diversification into the Southern Hemisphere where winter coincides with India's summer.
- Data center ambition: The China subsidiary is working on a product usable in data centers, still at the development stage; if successful, the segment could be entered in the next two years, though management caveated this with "fingers crossed."
Achal Bakeri: "This product is an impulse buy. It is not a planned purchase, because it is largely a portable product. So, the day the mercury goes up to 42, 44, whatever, they go out to the market buy and it is a plug-and-play product."
Real Estate & Capital Allocation
- Asset reclassification: Thol surplus land of 45,000 square meters with a market value of ~₹61 crores has been transferred from fixed assets to investment property; a Sindhu Bhavan Road land parcel with a market value of ~₹30 crores and a small flat have been reclassified from fixed assets to assets held-for-sale for divestment and monetization.
- Shareholder returns: The Board declared a second interim dividend of ₹2 per share, taking the total H1 shareholder payout to ₹110 crores, or 77% of consolidated PAT.
Industry Structure & Competitive Position
- Market share stable: Management stated that market share "more or less remains the same" for Q1, while Q2 has little retail sales after June so nothing meaningful to report.
- Growth tied to temperature: The industry's 5-year CAGR "isn't anything to write home about" because the business is tremendously linked to summer temperatures, and previous summers were not all good; the strong summer of 2024 drove the current performance.
- Competitive disclosures declined: Management declined to share the metro/urban/semi-urban/rural mix, the general trade versus organized trade sales breakup, or differential growth by geography, all citing competitive reasons.
Achal Bakeri: "Our business is very tremendously linked to how the summer temperatures are. And we had a good summer in '24. The previous summers were not all that good."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| New cooler billing | Billing and delivery of 17 new air cooler models to begin | December quarter (Q3 FY25) |
| GSK China loan repayment | Additional repayment of outstanding ~₹52 crores loan | Clear visibility, no specific date |
| Real estate monetization | Divestment of Sindhu Bhavan Road land parcel (~₹30 crores) and flat | No specific timeline |
| India growth trajectory | "Very respectable double-digit CAGR" going forward | Medium to long term |
| Data center product entry | China subsidiary product under development | ~2 years if successful ("fingers crossed") |
| Distributor recovery | Legal proceedings (Section 138 and further) underway | Uncertain; "our guess is as good as yours" |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Stand-alone revenue | ₹259 cr, up 32% YoY |
| Stand-alone PAT | ₹67 cr, up 36% YoY; includes ~₹2 cr additional income tax on treasury capital gains |
| Stand-alone EBITDA margin | 27.8%, up from 26.8% YoY |
| Stand-alone H1 FY25 revenue | ₹632 cr, up 72% YoY; highest ever H1, 49% above previous peak of ₹423 cr in Sep'22 |
| Stand-alone H1 FY25 PAT | ₹136 cr, up 112% YoY; highest ever H1, previous peak ₹83 cr in Sep'19 |
| Stand-alone return on net worth | 31%, vs 21% previous year |
| Stand-alone trailing 12-month core capital employed | negative ₹3 cr monthly average, vs positive ₹55 cr previous year |
| Treasury as on 30 Sep 2024 | ₹685 cr, up from ₹589 cr YoY; after ~₹100 cr buyback and interim dividend |
| Consolidated revenue | ₹315 cr, up 15% YoY |
| Consolidated PAT | ₹56 cr, up 61% YoY |
| Consolidated PAT margin | 17.7%, up 500 bps YoY |
| Consolidated H1 FY25 revenue | ₹846 cr, up 47% YoY; highest ever H1, above previous peak of ₹603 cr in Sep'22 |
| Consolidated H1 FY25 EBITDA | ₹175 cr, vs ₹70 cr previous year; margin 20.6%, up 840 bps |
| Consolidated H1 FY25 PAT | ₹144 cr; nearly matches full FY24 consol PAT of ₹148 cr |
| Consolidated ROCE | 93% on core capital employed, vs 37% previous year |
| Consolidated return on net worth | 33%, vs 15% previous year |
| IMPCO Mexico H1 FY25 revenue | ₹122 cr, up 14% YoY; PAT ₹14 cr vs ₹8 cr |
| GSK China H1 FY25 revenue | ₹41 cr, up from ₹23 cr; PAT ₹5 cr |
| GSK China Q2 FY25 revenue | ₹25 cr, vs ₹11 cr YoY |
| GSK China loan repayment in H1 FY25 | ~₹11 cr repaid out of ₹63 cr including interest; balance outstanding ~₹52 cr |
| Symphony Brazil H1 FY25 revenue | ₹19 cr, vs ₹7 cr |
| Symphony Brazil Q2 FY25 revenue | ₹18 cr, vs ₹6 cr YoY |
| Climate Technologies H1 FY25 revenue | ₹74 cr, down from ₹91 cr; PAT negative ₹17 cr, in line with last year |
| Subsidiaries combined H1 FY25 turnover | ₹256 cr, up 12% from ₹229 cr; EBITDA ₹23 cr vs ₹7 cr; PAT ₹7 cr vs negative ₹10 cr |
| Second interim dividend | ₹2 per share; total H1 shareholder payout ₹110 cr, 77% of consol PAT |
| Overdue receivable from large distributor | ~₹44 cr net outstanding for summer 2024 supplies; legal proceedings initiated |
| Stand-alone negative capital employed as of Sep 2024 | ₹171 cr, vs negative ₹70 cr |
| Stand-alone trailing 12-month PBIT | ₹252 cr on negative capital employed |
| Consolidated core capital employed as on 30 Sep 2024 | ₹114 cr; trailing 12-month ₹286 cr |
| Surplus real estate identified for monetization | ~₹31 cr market value (Thol surplus land ~₹61 cr, Sindhu Bhavan Road parcel ~₹30 cr); reclassified to assets held-for-sale |
| Real estate continuing as fixed assets | ~₹25 cr historical cost; market value ~₹104 cr |
| New air cooler models launched | 17 models; billing and delivery to start from December quarter |